Latest news on patient death in n-of-1 CRISPR trial; Good news for RSV; Vaccine R&D revolution; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
This is the rare week where Endpoints News is making news. If you haven’t heard, Drew Armstrong will be joining us from Bloomberg to become our new executive editor. We are thrilled to have him on board. Read founder and editor John Carroll’s note about our big announcement — and what that means for Endpoints.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.